Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

Brauer, Ruth, Wei, Li, Ma, Tiantian, Athauda, Dilan, Girges, Christine, Vijiaratnam, Nirosen, Auld, Grace, Whittlesea, Cate +2 more·2020·Brain
DOI 10.1093/brain/awaa262

Cited by (234)

Items 201–234 of 234

  1. Type 2 diabetes mellitus as a determinant factor for the age of ParkinsonÓ?s disease onset
    Amin Cervantes‐Arriaga, Óscar Esquivel-Zapata, Emmanuel Escobar-Valdivia, David J. García-Romero, Marco Antonio Muñuzuri-Camacho, Ana Jimena Hernandez-Medrano, Mayela Rodríguez‐Violante · 2023 · Revista de Fomento Social
  2. Analysis of LIN28A variants in patients with Parkinson’s disease
    Hao Peng, Yuanzhe Li, Hiroyo Yoshino, Mai Shimizu, Kenya Nishioka, Manabu Funayama, Nobutaka Hattori · 2023 · Journal of Human Genetics
  3. Effects of Metabolic Syndrome on Parkinson’s Disease and Nutraceutical Intervention Strategies
    Jéssica Emy Komuro, Daniel Fabiano Barbosa dos Santos, Andreas Batista Schelp, Sílvia Justina Papini, Arthur Oscar Schelp · 2023 · IntechOpen eBooks
  4. Risk of Parkinson’s Disease (PD) in patients with diabetes using thiazolidinedione (TZD): A systematic review, meta-analysis, and meta-regression
    Kezia Christy Gunawan, Timotius Ivan Hariyanto · 2023 · Romanian Journal of Neurology
  5. Characterization of the molecular interaction between α-synuclein and prion protein
    Renato Domingues · 2024
  6. How Lifetime Evolution of Parkinson’s Disease Could Shape Clinical Trial Design: A Shared Patient–Clinician Viewpoint
    Jules M. Janssen Daalen, Aranka Gerritsen, Gijs Gerritse, Jan Gouman, Hannie Meijerink, Leny E. Rietdijk, Sirwan K.L. Darweesh · 2024 · Brain Sciences
  7. Glycated Haemoglobin: A Biomarker of the Life Expectancy of Parkinson's Disease Patients with Type 2 Diabetes
    Yinghong Dai, Zheng Wang, Yijing Wang, Lina Zhu, Yan Yi, Meng Li, Qiyuan Peng, Jinchen Li, Ying Guan, Guihu Zhao et al. · 2024 · Research Square
  8. Antidiabetikum auf dem Prüfstand
    Günther Deuschl · 2024 · InFo Neurologie + Psychiatrie
  9. Wird die Progression gebremst?
    Thomas Köglsperger · 2024 · InFo Neurologie + Psychiatrie
  10. Pipeline of Pharmacotherapy in Parkinson’s Disease
    Florian Brugger, Stefan Hägele-Link · 2025 · Cambridge University Press eBooks
  11. Vers un traitement neuroprotecteur dans la MPI ? La cible GLP-1
    Wassilios G. Meissner · 2025 · Pratique Neurologique - FMC
  12. Impact of dipeptidyl peptidase 4 inhibitor use on mortality in diabetic Parkinson's disease patients: A nationwide cohort study
    Mincheol Park, Ho Kyung Lee, Yeonju Jin, Sanghee Yoo, Sung-Woo Kim, Sojeong Park, Jiwon Hong, Jin Yong Hong, Ickpyo Hong, Min Seok Baek · 2025 · Parkinsonism & Related Disorders
  13. Shared Gut Microbial and Functional Signatures Linking Parkinson’s Disease and Type 2 Diabetes Revealed by Function-Anchored Metagenomics
    Ying Cui, Shiya Wang, Wenlu Zhao, Yitong Du, Lin Wang, Bingyu Han, Mingkai Zhang, Xiaojiao Xu, Sichen Wang, Xiaolong Ma et al. · 2025 · Microorganisms
  14. “DPP- 4 inhibitor alleviates gut-brain axis Parkinson’s disease pathology” - can dipeptidyl peptidase 4 inhibitors be repurposed as disease-modifying drugs for body-first Parkinson’s disease patients?
    Amit Khairnar, Irena Rektorová, Tiago F. Outeiro · 2025 · Gut
  15. Additional file 1 of Causal relationship between diabetes mellitus, glycemic traits and Parkinson’s disease: a multivariable mendelian randomization analysis
    Wang, Qitong, Cai, Benchi, Lifan Zhong, Jitrawadee Intirach, Tao Chen · 2024 · Figshare
  16. Additional file 1 of Mitochondrial CISD1/Cisd accumulation blocks mitophagy and genetic or pharmacological inhibition rescues neurodegenerative phenotypes in Pink1/parkin models
    Martinez, Aitor, Álvaro Sánchez-Martínez, Jake T. Pickering, Madeleine J. Twyning, Ana Terriente-Félix, Chen, Po-Lin, Chen, Chun-Hong, Alexander J. Whitworth · 2024 · Figshare
  17. Role of GLP-1 receptors in the effect of hypericin on mouse neuroblastoma cell line (NB2a)
    Furkan Öztekin, Ertan Darıverenli, Ercüment Ölmez, Sedef Gidener · 2025 · Çukurova medical journal (Online)/Çukurova medical journal
  18. Incretin-based therapy and Parkinson's disease risk among patients with type 2 diabetes: Retrospective cohort study and meta-analysis
    Yael Barer, Tal Ast, Gabriel Chodick, Gilad Twig, Nir Giladi · 2025 · Parkinsonism & Related Disorders
  19. Shikonin attenuates diabetic Parkinsonian neuronal injury by facilitating p53/SLC25A28-mediated iron shuttling
    Yanwei Wang, Ziwei Han, Shanshan Pan, Minsong Guo, Meihong Wu, Xuesong Liu, Yuan Zhou, Jiahui Zhao, Yuehua Chen, Tengfei Xu · 2026 · Biochemical Pharmacology
  20. Alpha-synuclein and microglia in Parkinson’s disease and multiple system atrophy: A comprehensive review
    Jamir Pitton Rissardo, Ana Letícia Fornari Caprara · 2026 · Brain Circulation
  21. GLP-1 analogs restore inflammatory, mitochondrial and intercellular signaling networks in the Snca G51D/G51D knock-in mouse model of Parkinson’s disease
    Bhupesh Vaidya, Yan Li, Young Doo Kim, Cameron Osterman, Jean‐Pierre Revelli, Huda Yahya Zoghbi · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  22. Liens entre diabète de type 2 et maladie de Parkinson
    Ambrine Arrar, Saad El Mallem, Magalie A. Ravier, Safia Costes · 2026 · médecine/sciences
  23. Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study
    Tomasz Chmiela, Jarosław Dulski, Michael G. Heckman, Zhihui J. Fang, Zbigniew K. Wszołek, Jessica R. Wilson · 2026 · Frontiers in Neurology
  24. Novel treatments for Parkinson’s disease
    Yixuan Yin, Jianing Gao, Kezhong Zhang, F D Meng, Tao Feng · 2026 · Chinese Medical Journal
  25. Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: a bibliometric analysis of global research trends and research hotspots from 2006 to 2025
    Qinsheng Bi, L Zhang, J H Zhang, Xin Wang (91924), Changlin Zuo, Shijie Zhao, Z L Wang, Zilin Zhao, Hejia Wan · 2026 · Naunyn-Schmiedeberg s Archives of Pharmacology
  26. Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson’s disease: a bibliometric analysis
    Ting Yu, Qingxin Mai, Qian Wang, Mingxia Pan, Yuanfang Xiong, Lingyu Kuang, Hanjiao Liu · 2026 · Frontiers in Neuroscience
  27. Glucagon-like peptide-1 receptor agonists and the risk of Parkinson’s disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data
    Ying Chen, Xueping Wang, Jingjuan Wang, Gaiping Ma · 2026 · Frontiers in Endocrinology
  28. Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis
    Soo Hyeon Lee, Yujin Rho, Sangyoon Lee, Sooyoung Shin, Yeo Jin Choi · 2026 · Journal of Global Health
  29. Parkinson’s disease—Crucial advances and on-going challenges
    Grażyna Söderbom · 2026 · International review of neurobiology
  30. Ursodeoxycholic Acid and Parkinson's Disease Risk: An Emulated Target Trial in UK Electronic Health Records
    Chengsheng Ju, Anette E. Schrag, Camille Carroll, Xi Xiong, James Robert Carpenter, Oliver Bandmann, Thomas Foltynie, Li Wei · 2026 · Movement Disorders
  31. Appetitzügler bei Parkinson? Zwischen Mangelernährung und GLP1-Agonisten
    Andres Ceballos-Baumann · 2026 · Nervenheilkunde
  32. GLP-1 receptor agonists as potential disease-modifying agents in Parkinson’s and Alzheimer’s disease: mechanisms, clinical trial evidence, and the neuroprotection horizon
    Mohamed Alsharif, Omran Shrebaty, Mohammad Ammar Aloudah, Mayar Alqahtani, Raghad Saud AlOubili, Marafi Jammaa Ahmed, Bana AlBani, Ahmad El Bana · 2026 · Frontiers in Aging Neuroscience
  33. Repurposing existing drugs for Parkinson's disease management
    Moaz Elsayed Abouelmagd, Mark Messak, Ahmed Farid Gadelmawla, Mrinmoy Kundu · 2026 · Elsevier eBooks
  34. Metabolic endotyping for mechanism-informed Alzheimer’s and Parkinson’s disease trials
    José A. Santiago, Olivier Rascol, Tom Foltynie, Wassilios G. Meissner, Judith A. Potashkin, Jean C. Gutierrez-Silva, Mohammad Nafeli Shahrestani, Yusen Wu, Tatjana Rundek, Ihtsham Ul Haq · 2026 · Med